Hepatitis Therapeutics Markets: Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others - Global Forecast to 2027 - ResearchAndMarkets.com

The "Hepatitis Therapeutics Market, By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Other Types), Drug Class (Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others) and Region: Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, September 20, 2021
Information
Tags: 
Infectious Diseases, Pharmaceutical, Health, Hepatitis, Therapy, Interferon, Hepatitis D, AbbVie, Hepatitis B, CAGR, Merck & Co., Gilead Sciences, Hepatitis C, Bristol Myers Squibb, Merck, Growth, Johnson & Johnson, Intelligence, Research, NS5A, Hepatitis A, Monoclonal antibody, Industry, Pharmaceutical industry, Video game console
Geotags: 
KEY
⚠generated by AI ↴
Summary
Key Points: 
  • The "Hepatitis Therapeutics Market, By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Other Types), Drug Class (Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others) and Region: Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Hepatitis Therapeutics market size is estimated to grow at a CAGR of 3.5% during the forecast year from 2021 to 2027.
  • The latest report on Hepatitis Therapeutics Market understands market size estimates, forecasts, market shares, competition analysis, along with industry trends of Hepatitis Therapeutics with emphasis on market timelines and technology roadmaps analysis.
  • The Hepatitis Therapeutics market is segmented by disease type, drug class and region.


The "Hepatitis Therapeutics Market, By Disease Type (Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Other Types), Drug Class (Interferon, Monoclonal Antibody, Non-structural protein 5A (NS5A) inhibitors, Others) and Region: Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The Hepatitis Therapeutics market size is estimated to grow at a CAGR of 3.5% during the forecast year from 2021 to 2027.

The latest report on Hepatitis Therapeutics Market understands market size estimates, forecasts, market shares, competition analysis, along with industry trends of Hepatitis Therapeutics with emphasis on market timelines and technology roadmaps analysis.

The Hepatitis Therapeutics market is segmented by disease type, drug class and region. The research covers the current and historic Hepatitis Therapeutics market size and its growth trend with company outline of Key players/manufacturers Gilead Science; Johnson & Johnson; Bristol-Myers Squibb Company; Merck & Co., Inc., AbbVie Inc, F. Hoffmann-La Roche Ltd among others.

Analysis of the global market with special focus on high growth application in each vertical and fast-growing market segments. It includes detailed competitive landscape with identification of the key players with respect to each type of market, in-depth market share analysis with individual revenue, market shares, and top players rankings.

Impact analysis of the market dynamics with factors currently driving and restraining the growth of the market, along with their impact in the short, medium, and long-term landscapes. Competitive intelligence from the company profiles, key player strategies, game-changing developments such as product launches and acquisitions.

The objective of this study is to identify the market opportunities and estimate market size by segments and countries for last few years and to forecast the values to the next five years. The report incorporates both the qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study.

Key Topics Covered:

1. EXECUTIVE SUMMARY

2. INTRODUCTION

2.1. Key Takeaways

2.2. Report Description

2.3. Market Scope & Definition

2.4. Stakeholders

2.5. Research Methodology

2.5.1. Market Size

2.5.2. Key Data Points From Primary Sources

2.5.3. Key Data Points From Secondary Sources

2.5.4. List Of Primary Sources

2.5.5. List Of Secondary Sources

3. MARKET OVERVIEW

3.1. Industry Segmentation

3.2. Market Trends Analysis

3.3. Major Funding & Investments

3.4. Market Dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.5. Value Chain Analysis

3.6. Pricing Analysis

4. IMPACT OF COVID-19 ON HEPATITIS THERAPEUTICS MARKET

4.1. Impact Of COVID-19 On Market, By Disease Type

4.2. Impact Of COVID-19 On Market, By Drug Class

4.3. Impact Of COVID-19 On Market, By Geography

5. HEPATITIS THERAPEUTICS MARKET, BY DISEASE TYPE

5.1. Introduction

5.2. Hepatitis A

5.3. Hepatitis B

5.4. Hepatitis C

5.5. Others

6. HEPATITIS THERAPEUTICS MARKET, BY DRUG CLASS

6.1. Introduction

6.2. Interferon

6.3. Monoclonal Antibody

6.4. Non-structural protein 5A (NS5A) inhibitors

6.5. Nucleotide Analog Reverse Transcriptase Inhibitors

6.6. Nucleotide Analog NS5B Polymerase Inhibitors

7. HEPATITIS THERAPEUTICS MARKET, BY GEOGRAPHY

7.1. Introduction

8. COMPETITIVE ANALYSIS

8.1. Introduction

8.2. Top Companies Ranking

8.3. Market Share Analysis

8.4. Recent Developments

8.4.1. New Product Launch

8.4.2. Mergers & Acquisitions

8.4.3. Collaborations, Partnerships & Agreements

8.4.4. Rewards & Recognition

9. COMPANY PROFILES

9.1. Intuitive Surgical

9.2. Gilead Science

9.3. Johnson & Johnson

9.4. Bristol-Myers Squibb Company

9.5. Merck & Co., Inc.

9.6. AbbVie Inc

9.7. F. Hoffmann-La Roche Ltd

For more information about this report visit https://www.researchandmarkets.com/r/gujip

Copyright: 
Copyright Business Wire 2021